Good Start Genetics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

goodstartgenetics.com

Stage

Acquired | Acquired

Total Raised

$60M

About Good Start Genetics

Good Start Genetics offers preconception carrier screening tests for all ACOG- and ACMG- recommended disorders, as well as an extended Ashkenazi Jewish test menu. The company's test menu was designed with input from an expert panel of reproductive health physicians and genetic counselors from across the country. Good Start has designed its test menu for easy adherence to society guidelines. The company's next-generation sequencing (NGS) platform is a cost-effective platform accessible for routine genetic carrier screening. Utilizing NGS, Good Start will evaluate patient DNA samples to detect both common and novel disease-causing mutations associated with recessive genetic disorders, hence providing a depth of analysis far beyond current targeted mutation analysis platforms.

Good Start Genetics Headquarter Location

237 Putnam Ave

Cambridge, Massachusetts, 02139,

United States

866-765-0845

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Good Start Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Good Start Genetics is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

Good Start Genetics Patents

Good Start Genetics has filed 42 patents.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2015

7/6/2021

Molecular biology, Genetics, Midwifery, Obstetrics, Rare diseases

Grant

Application Date

5/12/2015

Grant Date

7/6/2021

Title

Related Topics

Molecular biology, Genetics, Midwifery, Obstetrics, Rare diseases

Status

Grant

Latest Good Start Genetics News

Safeguard Scientifics Partner Company Good Start Genetics To Be Acquired By Invitae Corporation

Jul 31, 2017

News provided by 17:15 ET Share this article RADNOR, Pa., July 31, 2017 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE: SFE ) today announced that its partner company, Good Start Genetics, Inc. ("Good Start"), signed a definitive agreement to be acquired by San Francisco-based genetics information company, Invitae Corporation (NYSE: NVTA ). The transaction is expected to close in the first part of August 2017, subject to customary closing conditions. Safeguard expects to receive initial consideration consisting of $3.8 million of Invitae common stock, based on the 30-day trailing average stock price, and an additional $1.3 million of Invitae common stock which will be held in escrow for up to 13 months. Invitae is one of the fastest growing genetic information companies in the U.S. whose longer-term strategy is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising approximately 1,500 genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas, as well as clinical analysis of a 20,000-gene medical exome. Stephen T. Zarrilli, Safeguard's President and CEO, said, "From Safeguard's perspective, this outcome represents a significant shortfall based on our return expectations. However, considering the anticipated time and cost required to introduce additional technologies and tests into adjacent markets and to further develop Good Start, we believe that a larger, more financially capable enterprise that is focused on genetic testing was necessary to move Good Start's vision forward." "Good Start is an excellent strategic fit with Invitae," said Gary J. Kurtzman, MD, Managing Director at Safeguard and board member at Good Start. "We believe that Invitae is the best partner to advance the mission Good Start began seven years ago." About Safeguard Scientifics Safeguard Scientifics (NYSE: SFE ) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Safeguard targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and predictive analytics. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. For more information, please visit  www.safeguard.com or follow us on Twitter @ safeguard . Forward-looking Statements Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the deployment of capital, the fact that our partner companies may vary from period to period, our substantial capital requirements and absence of liquidity from our partner company holdings, fluctuations in the market prices of our publicly traded partner company holdings, competition, our inability to obtain maximum value for our partner company holdings, our ability to attract and retain qualified employees, market valuations in sectors in which our partner companies operate, our inability to control our partner companies, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our partner companies, including the fact that most of our partner companies have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's partner companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond the Company's ability to predict or control. As a result of these and other factors, the Company's past financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release. SAFEGUARD CONTACT: Senior Vice President, Investor Relations and Corporate Communications 610.975.4952

  • Where is Good Start Genetics's headquarters?

    Good Start Genetics's headquarters is located at 237 Putnam Ave, Cambridge.

  • What is Good Start Genetics's latest funding round?

    Good Start Genetics's latest funding round is Acquired.

  • How much did Good Start Genetics raise?

    Good Start Genetics raised a total of $60M.

  • Who are the investors of Good Start Genetics?

    Investors of Good Start Genetics include Invitae, CRG, Safeguard Scientifics, OrbiMed Advisors, SV Health Investors and 3 more.

  • Who are Good Start Genetics's competitors?

    Competitors of Good Start Genetics include Ativa Medical, AutoGenomics, Oxford BioDynamics, Third Eye Diagnostics, Corpora Systems and 13 more.

You May Also Like

A
Ativa Medical

Ativa Medical is a medical diagnostics company that is working to make diagnostic test results available in moments, rather than hours and days.

E
Everest Biomedical

Everest currently markets a newborn hearing screening device that combines evoked otoacoustic emissions and auditory brainstem response. The company is based in St. Louis, MO, and has under development a hand-held, battery-operated monitoring device enabling the anesthetician to know what is happening in the entire brain while the patient is under anesthesia.

C
Cervimark

Cervimark is a medical diagnostics company that is developing a screening test for the prediction of pregnancies at high risk for preterm delivery. The test is based on quantifying biomarkers found in secretions of pregnant patients and correlating the resulting data to risk of pre-term labor. Proof of concept for this test has been demonstrated in a small human trial.

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

m
m2m Imaging

Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.

A
Aironet Wireless Communications

BioArray is a molecular diagnostics company engaged in the development and commercialization of assay solutions for multiplexed analysis of DNA and protein markers using a customizable bead array ("BeadChip") format and automated assay delivery system, with available products for immunohematology, transplantation, genetic testing and immunology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.